Loading

Companies Should Embrace RWE Strategies Early and Often

June 18, 2025
Breakout Session
AI and Digital Health
Integrating real-world evidence (RWE) strategies during drug development and commercialization is critical to maximizing shareholder and stakeholder value. Biopharma executives need to know how to leverage RWE to accelerate clinical development, bolster regulatory strategy, optimize commercialization and market access, and drive down development costs. By highlighting their recent experiences with concrete examples, panelists will provide insights into how stakeholders, especially regulators, and payers, who are becoming increasingly sophisticated and willing to engage with companies early, are assessing the quality of RWE, whether it is “fit-for-purpose,” and if it can contribute to the “totality of evidence” required for a successful outcome, including a competitive advantage after approval. In particular, the panel will highlight where some companies have been successful and where others have not, and provide some “best practice” thinking on how to integrate and operationalize RWE into their plans.
Moderator
Marnie L.. Hoolahan, MBA
President
The NemetzGroup LLC
Speakers
Mei Sheng Duh, RPh
Managing Partner and Chief Epidemiologist, RPh, MPH, ScD
Analysis Group
Raymond Mankoski, MD, PhD
Senior Medical Consultant
The NemetzGroup LLC
Ruth Pulikottil Jacob, PhD
EMEA HEOR Lead
Cepheid Danaher Company
Sara Silacci
Founder and Managing Partner
Margin4Mission, LLC

BIO DOUBLE HELIX SPONSORS

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

Loading

BIO HELIX SPONSORS